Company intelligence / Profile preview

CellaVision

Ownership: Private
Employees: ~250
Development stage: Commercial

Overview

CellaVision’s products are widely adopted in clinical laboratories globally. Over 8000 units sold in more than 40 countries. Their solutions are considered the gold standard for digital cell morphology in hematology labs. No clinical trial results as they provide diagnostic devices/software.

Therapeutic areas: Hematology
Modalities: DeviceSoftware
Industry: Pathology

Partnerships

Sysmex Corporation – global distribution agreement for hematology analyzers and solutions

Beyond the preview

Go deeper on CellaVision.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CellaVision.

Explore the full profile